Effects of Amlodipine in the Management of Chronic Heart Failure
Chronic Heart Failure
About this trial
This is an interventional treatment trial for Chronic Heart Failure focused on measuring Calcium channel blockers, Heart failure, Hemodynamics
Eligibility Criteria
Inclusion Criteria: Patients over 18 years Chronic heart failure with New York Heart Association class III or IV. Ischemic or dilated cardiopathy known for at least 3 months Systolic arterial pressure > 110 mmHg under treatment Stroke volume between 20 and 40% under treatment Informed written consent Exclusion Criteria: History of allergy to one of the studied pharmaceutical classes History of troubles in ventricular rythm (tachycardia, fibrillation) or acute heart failure Chronic renal, hepatic or respiratory failure Diabetes Valvulopathy Myocarditis,constrictive pericarditis Life prognosis < 6 months due to a non cardiac pathology Absence of woman contraception, pregnancy, breast-feeding Treatment with calcium channel blockers or antiarrythmics class IC Unstable patient under standardized treatment Unable to do a stress test
Sites / Locations
- Service de Réanimation Médicale - Hôpital Raymond Poincaré
- Service de Réadaptation Cardio-Vasculaire - Clinique St Yves